A post by @FirstSquawk on X.

Merck & Co. said its HIF-2α inhibitor and VEGFR-TKI combination regimen would become the first of its kind in the EU if approved. The company disclosed the claim via a First Squawk tweet, without specifying the indication, the trial data or a regulatory timeline. The distinction matters because it would give Merck a novel dual-mechanism class position in Europe rather than a head-to-head label against an existing combination. Watch for the EMA filing and committee opinion, plus the underlying trial results, to establish which tumor type and how durable the benefit is.